Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease
This reimbursement policy governs coverage for serum-based biomarkers and multianalyte algorithmic assays used to evaluate and monitor hepatic fibrosis in individuals with chronic liver disease for BlueCross BlueShield of Tennessee members.
No material clinical or coverage changes in this revision.
Coverage determinations for serum testing
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.